<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846310</url>
  </required_header>
  <id_info>
    <org_study_id>AB928CSP0004</org_study_id>
    <nct_id>NCT03846310</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer</brief_title>
  <official_title>A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to&#xD;
      evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical&#xD;
      activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or&#xD;
      without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with&#xD;
      non-squamous Non-Small Cell Lung Cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the dose-escalation phase, escalating doses of etrumadenant in combination with&#xD;
      carboplatin and pemetrexed at standard doses (Arm A), and etrumadenant in combination with&#xD;
      carboplatin, pemetrexed and pembrolizumab (Arm B), may be assessed in participants with&#xD;
      advanced NSCLC. Eligible participants will receive oral administration of etrumadenant as&#xD;
      well as IV infused carboplatin, pemetrexed, with or without pembrolizumab in this phase. The&#xD;
      recommended dose for expansion (RDE) of etrumadenant will be determined upon completion of&#xD;
      the dose-escalation phase.&#xD;
&#xD;
      In the dose-expansion phase, zimberelimab in combination with carboplatin and pemetrexed (Arm&#xD;
      1), and etrumadenant at RDE in combination with carboplatin, pemetrexed, and zimberelimab&#xD;
      (Arm 2) may be assessed in eligible NSCLC participants who harbor an EGFR mutation and have&#xD;
      progressed on EGFR Tyrosine Kinase Inhibitor (TKI) treatment(s).&#xD;
&#xD;
      Overall duration of treatment will depend on how well the treatment is tolerated.&#xD;
&#xD;
      Treatment may continue until unacceptable toxicity or progressive disease or other reasons&#xD;
      specified in the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3+3 dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Adverse Events</measure>
    <time_frame>From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experience a Dose Limiting Toxicity</measure>
    <time_frame>From first study treatment administration through Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-drug antibodies to zimberelimab</measure>
    <time_frame>Recorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of etrumadenant</measure>
    <time_frame>Recorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of zimberelimab</measure>
    <time_frame>Recorded at baseline (screening), during the first 4 cycles of treatment (4 months) and 30 days post last dose (i.e. in total approximately 5 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From start of treatment up to the first occurrence of progressive disease or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From study start of treatment up to death from any cause (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for &gt;6 months</measure>
    <time_frame>From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Objective Response</measure>
    <time_frame>From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Nonsquamous Nonsmall Cell Neoplasm of Lung</condition>
  <condition>Sensitizing EGFR Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrumadenant</intervention_name>
    <description>Etrumadenant is an A2aR and A2bR antagonist</description>
    <arm_group_label>Dose Escalation Arm A</arm_group_label>
    <arm_group_label>Dose Escalation Arm B</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
    <other_name>AB928</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zimberelimab</intervention_name>
    <description>Zimberelimab is a fully human anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
    <other_name>AB122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered as part of standard chemotherapy regimen</description>
    <arm_group_label>Dose Escalation Arm A</arm_group_label>
    <arm_group_label>Dose Escalation Arm B</arm_group_label>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed administered as part of standard chemotherapy regimen</description>
    <arm_group_label>Dose Escalation Arm A</arm_group_label>
    <arm_group_label>Dose Escalation Arm B</arm_group_label>
    <arm_group_label>Dose Expansion Arm 1</arm_group_label>
    <arm_group_label>Dose Expansion Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is a humanized anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Dose Escalation Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants; age ≥ 18 years&#xD;
&#xD;
          -  Pathologically confirmed nonsquamous NSCLC that is metastatic, locally advanced, or&#xD;
             recurrent with progression&#xD;
&#xD;
          -  Arm A participants must fulfill one of the following:&#xD;
&#xD;
               -  Participant has a genetic alteration (mutation or rearrangement) and has received&#xD;
                  all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1&#xD;
                  therapy is not allowed.&#xD;
&#xD;
               -  Participant has not received any therapy for the disease under study and standard&#xD;
                  therapy is refused.&#xD;
&#xD;
               -  Participant has progressed on PD-1/-L1 therapy (monotherapy or combination&#xD;
                  regimen). Previous treatment with chemotherapy is not allowed.&#xD;
&#xD;
               -  Participant has progressed on PD-1/-L1 therapy (monotherapy or combination&#xD;
                  regimen) and has received less than 4 cycles of carboplatin/pemetrexed and&#xD;
                  further chemotherapy is appropriate.&#xD;
&#xD;
               -  Participant has received any number of prior treatments and is without&#xD;
                  alternative or curative therapy.&#xD;
&#xD;
          -  Arm B participants must fulfill one of the following:&#xD;
&#xD;
               -  Participant has a genetic alteration (mutation or rearrangement) and has received&#xD;
                  all available targeted therapy. Previous treatment with chemotherapy or PD-1/-L1&#xD;
                  therapy is not allowed.&#xD;
&#xD;
               -  Participant has not received any therapy for the disease under study and standard&#xD;
                  therapy is refused.&#xD;
&#xD;
               -  Participant has received any number of prior treatments and is without&#xD;
                  alternative or curative therapy.&#xD;
&#xD;
          -  Arm 1 and Arm 2 participants must have a sensitizing epidermal growth factor receptor&#xD;
             (EGFR) mutation with disease progression or treatment intolerance after one or more&#xD;
             approved TKIs. Previous treatment with chemotherapy or PD-1/L-1 therapy is not&#xD;
             allowed.&#xD;
&#xD;
          -  No TKI therapy within 5 days of Cycle 1 Day 1&#xD;
&#xD;
          -  The last dose of previous investigational therapy is at least 4 weeks or 5 half-lives&#xD;
             prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST v1.1)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.&#xD;
&#xD;
          -  Confirm that an archival tissue sample is available and ≤ 24 months old; if not, a new&#xD;
             biopsy of a tumor lesion should be obtained at screening&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any live vaccines against infectious diseases within 4 weeks (28 days) of&#xD;
             initiation of investigational product&#xD;
&#xD;
          -  Is pregnant or breastfeeding or expecting to conceive or father children within the&#xD;
             projected duration of the study, starting with the pre-screening or screening visit&#xD;
             through 30 days after the last dose of etrumadenant, 90 days after the last dose of&#xD;
             zimberelimab or pembrolizumab, or 6 months after the last dose of pemetrexed,&#xD;
             whichever is longer&#xD;
&#xD;
          -  Any active autoimmune disease or a documented history of autoimmune disease or&#xD;
             syndrome that required systemic treatment in the past 2 years (ie, with use of&#xD;
             disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for&#xD;
             vitiligo or resolved childhood asthma/atopy&#xD;
&#xD;
          -  Prior malignancy active within the previous 2 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate&#xD;
             cancer&#xD;
&#xD;
          -  Prior use of an adenosine pathway targeting agent&#xD;
&#xD;
        Due to potential for drug-drug interactions with etrumadenant, participants must not have&#xD;
        had:&#xD;
&#xD;
          -  Treatment with breast cancer resistance protein substrates or P-glycoprotein with a&#xD;
             narrow therapeutic window, administered orally within 4 weeks or 5 half-lives of the&#xD;
             drug (whichever is longer) prior to initiation of study treatment.&#xD;
&#xD;
          -  Treatment with known strong cytochrome P450 3A4 (CYP3A4) inducers and strong CYP3A4&#xD;
             inhibitors within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to&#xD;
             initiation of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Arcus Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Clinical Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center-Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCRI - University of Oklahoma</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Austin (Midtown)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS (dba Summit Cancer Centers)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital (The University of Hong Kong)</name>
      <address>
        <city>Hong Kong</city>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital (The Chinese University of Hong Kong)</name>
      <address>
        <city>Sha Tin</city>
        <zip>999077</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent Hospital of the Catholic University of Korea</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Centre</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University - Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <zip>23561</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi Mei Hospital, Liouying</name>
      <address>
        <city>Tainan City</city>
        <zip>73657</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

